Patents by Inventor Toshio Inagi
Toshio Inagi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8442629Abstract: Provided is to enhance the therapeutic effect of an iontophoretic preparation for treatment of breast cancer or mastitis. An iontophoretic preparation for treatment of breast cancer and/or mastitis containing, as an active ingredient, a nonsteroidal anti-inflammatory analgesic agent and/or an anticancer agent, wherein an electrolyte is topically administered through the nipple part into the mammary gland; subsequently, a donor is applied to the nipple part; and the active ingredient is topically administered through the nipple part into the mammary gland by application of current.Type: GrantFiled: April 17, 2009Date of Patent: May 14, 2013Assignee: Kowa Co., Ltd.Inventors: Kenichi Suzuki, Makoto Kanebako, Toshio Inagi
-
Patent number: 8362027Abstract: The present invention is to provide means to treat breast cancer and/or mastitis by topically administering a non-steroidal antiinflammatory analgetic agent and/or an anticancer agent and allowing them efficiently to arrive into the mammary gland. The present invention provides an iontophoretic preparation for treating breast cancer and/or mastitis which contains a non-steroidal antiinflammatory analgetic agent and/or an anticancer agent as an active ingredient and has a donor to be applied on a nipple part for topical administration of the active ingredient from the nipple part to the mammary gland by application of electric potential.Type: GrantFiled: August 8, 2011Date of Patent: January 29, 2013Assignees: Kowa Co., Ltd., Tokyo University of Science Educational Foundation Administrative OrganizationInventors: Toshio Inagi, Makoto Kanebako, Hiroshi Terada, Kimiko Makino, Masakazu Toi
-
Publication number: 20120328675Abstract: Provided is a film preparation in which an unpleasant taste derived from a medicament is masked. The film preparation includes coating layers containing no terpene formed on both sides of a medicament-containing layer containing a medicament having an unpleasant taste and a terpene.Type: ApplicationFiled: March 3, 2011Publication date: December 27, 2012Applicants: KOWA CO., LTD., KYUKYU PHARMACEUTICAL CO., LTD.Inventors: Tsutomu Awamura, Hisanobu Nishikawa, Kazuhiko Kokaji, Akihiro Ishise, Takayuki Arai, Seiji Miura, Toshio Inagi
-
Patent number: 8105630Abstract: A composition containing an extremely poorly water-soluble drug and obtained by treating, with a supercritical fluid or subcritical fluid of carbon dioxide, a mixture comprising a porous silica material and the extremely poorly water-soluble drug; and its production process. The porous silica material has an average pore diameter in a range of from 1 to 20 nm, pores having diameters within ±40% of the average pore size account for at least 60% of a total pore volume of the porous silica material, and in X-ray diffractometry, the porous silica material has at least one peak at a position of diffraction angle (2?) corresponding to a d value of at least 1 nm. The composition according to the present invention, which contains the extremely poorly water-soluble drug, is excellent in the dissolution of the extremely poorly water-soluble drug.Type: GrantFiled: April 28, 2004Date of Patent: January 31, 2012Assignees: Kowa Co., Ltd., Kabushiki Kaisha Toyota Chuo KenkyushoInventors: Hiroshi Miura, Makoto Kanebako, Masayuki Kanishi, Toshio Inagi, Hirofumi Takeuchi, Tsutomu Kajino, Yoshiaki Fukushima, Haruo Takahashi
-
Patent number: 8101207Abstract: A composition containing a very low water-soluble drug, which composition is produced by treating, with a supercritical or subcritical carbon dioxide fluid, a mixture containing a very low water-soluble drug and a porous material (exclusive of a porous silica material characterized in that the material has an average pore diameter of 1 to 20 nm, the total pore volume of the material that have a diameter falling within a range of ±40% of the average pore diameter account for 60% or more the volume of all the pores of the material, and, when subjected to X-ray diffractometry, the material exhibits one or more peaks at a diffraction angle (2?) corresponding to d of 1 nm or more); and a method for producing the composition. The very-low-water-soluble-drug-containing composition of the present invention ensures improved dissolution of the very low water-soluble drug.Type: GrantFiled: April 28, 2004Date of Patent: January 24, 2012Assignee: Kowa Co., Ltd.Inventors: Hiroshi Miura, Makoto Kanebako, Masayuki Kanishi, Yasuo Shinoda, Toshio Inagi, Hirofumi Takeuchi
-
Publication number: 20110295189Abstract: The present invention is to provide means to treat breast cancer and/or mastitis by topically administering a non-steroidal antiinflammatory analgetic agent and/or an anticancer agent and allowing them efficiently to arrive into the mammary gland. The present invention provides an iontophoretic preparation for treating breast cancer and/or mastitis which contains a non-steroidal antiinflammatory analgetic agent and/or an anticancer agent as an active ingredient and has a donor to be applied on a nipple part for topical administration of the active ingredient from the nipple part to the mammary gland by application of electric potential.Type: ApplicationFiled: August 8, 2011Publication date: December 1, 2011Applicants: Tokyo Univ. of Sci. Edu. Fdn. Admin. Org., Kowa Co., Ltd.Inventors: Toshio INAGI, Makoto Kanebako, Hiroshi Terada, Kimiko Makino, Masakazu Toi
-
Patent number: 8034824Abstract: The present invention is to provide means to treat breast cancer and/or mastitis by topically administering a non-steroidal antiinflammatory analgetic agent and/or an anticancer agent and allowing them efficiently to arrive into the mammary gland. The present invention provides an iontophoretic preparation for treating breast cancer and/or mastitis which contains a non-steroidal antiinflammatory analgetic agent and/or an anticancer agent as an active ingredient and has a donor to be applied on a nipple part for topical administration of the active ingredient from the nipple part to the mammary gland by application of electric potential.Type: GrantFiled: October 11, 2006Date of Patent: October 11, 2011Assignees: Kowa Co., Ltd., Tokyo University of Science Educational Foundation Administrative OrganizationInventors: Toshio Inagi, Makoto Kanebako, Hiroshi Terada, Kimiko Makino, Masakazu Toi
-
Publication number: 20110159058Abstract: The film preparation of the present invention includes: a drug-containing intermediate layer containing loperamide hydrochloride, a terpene and a film-forming agent; and coating layers containing a film-forming agent and a plasticizer (but not a terpene) and laminated on both sides of the drug-containing intermediate layer. As a bitter taste derived from loperamide hydrochloride is thereby masked, uncomfortable sensation when taking the film preparation can be reduced. Furthermore, as this film preparation is rapidly dissolved (i.e., has a rapidly dissolving property) only with moisture in the oral cavity, it begins to work quickly and is very convenient when it is carried and taken.Type: ApplicationFiled: August 25, 2009Publication date: June 30, 2011Applicants: KYUKYU PHARMACEUTICAL CO., LTD., KOWA CO., LTD.Inventors: Tsutomu Awamura, Hisanobu Nishikawa, Toshio Inagi
-
Publication number: 20110034859Abstract: Provided is to enhance the therapeutic effect of an iontophoretic preparation for treatment of breast cancer or mastitis. An iontophoretic preparation for treatment of breast cancer and/or mastitis containing, as an active ingredient, a nonsteroidal anti-inflammatory analgesic agent and/or an anticancer agent, wherein an electrolyte is topically administered through the nipple part into the mammary gland; subsequently, a donor is applied to the nipple part; and the active ingredient is topically administered through the nipple part into the mammary gland by application of current.Type: ApplicationFiled: April 17, 2009Publication date: February 10, 2011Applicants: Tokyo University of Sci Edu Found Admin Org, TAIHO PHARMACEUTICAL CO., LTD.Inventors: Kenichi Suzuki, Makoto Kanebako, Toshio Inagi
-
Publication number: 20090317354Abstract: The present invention relates to a composition for repairing injured skin containing a saccharide and povidone-iodine. The present invention has the following characteristics: suppresses time-dependent increase of consistency, it is easy to use, it is a soft preparation, and has superior applicability to a deep wounded lesion and a granulation tissue. The composition of the present invention contains 50 to 90% by weight of saccharide, 0.5 to 10% by weight of povidone-iodine, 0.1 to 20% by weight of water and 0.01 to 10% by weight of phospholipid.Type: ApplicationFiled: August 25, 2009Publication date: December 24, 2009Applicants: Kowa Co., Ltd., TEIKA PHARMACEUTICAL CO., LTD.Inventors: Masahiro Nishimura, Shihomi Nito, Toshio Inagi, Takahito Kimura
-
Publication number: 20090281063Abstract: The present invention is to provide means to treat breast cancer and/or mastitis by topically administering a non-steroidal antiinflammatory analgetic agent and/or an anticancer agent and allowing them efficiently to arrive into the mammary gland. The present invention provides an iontophoretic preparation for treating breast cancer and/or mastitis which contains a non-steroidal antiinflammatory analgetic agent and/or an anticancer agent as an active ingredient and has a donor to be applied on a nipple part for topical administration of the active ingredient from the nipple part to the mammary gland by application of electric potential.Type: ApplicationFiled: October 11, 2006Publication date: November 12, 2009Applicants: KOWA CO., LTD., TOKYO UNIVERSITY OF SCIENCE EDUCATIONAL FOUNDATION ADMINISTRATIVE ORGANIZATIONInventors: Toshio Inagi, Makoto Kanebako, Hiroshi Terada, Kimiko Makino, Masakazu Toi
-
Patent number: 7553865Abstract: An object of the present invention is to provide an indomethacin external preparation that has an excellent use feeling and excellent absorbability and causes no phase separation into an oil layer and an aqueous layer, thus exhibiting satisfactory stability of preparation with time. Provided is an indomethacin external preparation containing: 0.1 to 3 wt % of indomethacin; 25 to 50 wt % of alcohol; 0.01 to 5 wt % of gelling agent; 5 to 30 wt % of oil component; 20 to 50 wt % of water; and 0.01 to 10 wt % of one or more components selected from the group consisting of glyceryl monostearate, sorbitan monostearate, stearyl alcohol, and polyethylene glycol monostearate.Type: GrantFiled: July 22, 2003Date of Patent: June 30, 2009Assignee: Kowa Company, Ltd.Inventors: Hiroyuki Shirai, Tatsuya Nakai, Masami Serizawa, Yasuo Shinoda, Toshio Inagi
-
Publication number: 20070128273Abstract: A composition containing a very low water-soluble drug, which composition is produced by treating, with a supercritical or subcritical carbon dioxide fluid, a mixture containing a very low water-soluble drug and a porous material (exclusive of a porous silica material characterized in that the material has an average pore diameter of 1 to 20 nm, the total pore volume of the material that have a diameter falling within a range of ±40% of the average pore diameter account for 60% or more the volume of all the pores of the material, and, when subjected to X-ray diffractometry, the material exhibits one or more peaks at a diffraction angle (2?) corresponding to d of 1 nm or more); and a method for producing the composition. The very-low-water-soluble-drug-containing composition of the present invention ensures improved dissolution of the very low water-soluble drug.Type: ApplicationFiled: April 28, 2004Publication date: June 7, 2007Applicant: Kowa Co., Ltd.Inventors: Hiroshi Miura, Makoto Kanebako, Masayuki Kanishi, Yasuo Shinoda, Toshio Inagi, Hirofumi Takeuchi
-
Publication number: 20060293327Abstract: A composition containing an extremely poorly water-soluble drug and obtained by treating, with a supercritical fluid or subcritical fluid of carbon dioxide, a mixture comprising a porous silica material and the extremely poorly water-soluble drug; and its production process. The porous silica material has an average pore diameter in a range of from 1 to 20 nm, pores having diameters within ±40% of the average pore size account for at least 60% of a total pore volume of the porous silica material, and in X-ray diffractometry, the porous silica material has at least one peak at a position of diffraction angle (2?) corresponding to a d value of at least 1 nm. The composition according to the present invention, which contains the extremely poorly water-soluble drug, is excellent in the dissolution of the extremely poorly water-soluble drug.Type: ApplicationFiled: April 28, 2004Publication date: December 28, 2006Applicants: Kowa Co. Ltd., KABUSHIKI KAISHA TOYOTA CHUO KENKYUSHOInventors: Hiroshi Miura, Makoto Kanebako, Masayuki Kanishi, Toshio Inagi, Hirofumi Takeuichi, Tsutomu Kajino, Yoshiaki Fukushima, Haruo Takahashi
-
Publication number: 20060051410Abstract: A highly stable pharmaceutical composition which comprises a mixture comprising a substance selected from the group consisting of 2,2-dichloro-12-(4-chlorophenyl)-dodecanoic acid, salts thereof, and esters thereof, and croscarmellose sodium.Type: ApplicationFiled: January 15, 2003Publication date: March 9, 2006Inventors: Shin-ichiro Kobayashi, Niichiro Takano, Hiroyuki Kawashima, Toshio Inagi
-
Publication number: 20060034945Abstract: The present invention provides a composition for repairing injured skin containing saccharide and povidone-iodine of the present invention having characteristices of suppressing time-dependent increase of consistency, easy to use, soft preparation, and superior applicability to a deep wounded lesion and a granulation tissue. The composition for repairing injured skin comprises 50 to 90% by weight of saccharide, 0.5 to 10% by weight of povidone-iodine, 0.1 to 20% by weight of water and 0.01 to 10% by weight of phospholipid.Type: ApplicationFiled: November 10, 2003Publication date: February 16, 2006Applicants: Kowa Co., Ltd, Teika Pharmaceutical Co., Ltd.Inventors: Masahiro Nishimura, Shihomi Nito, Toshio Inagi, Takahito Kimura
-
Publication number: 20050239868Abstract: An object of the present invention is to provide an indomethacin external preparation that has an excellent use feeling and excellent absorbability and causes no phase separation into an oil layer and an aqueous layer, thus exhibiting satisfactory stability of preparation with time. Provided is an indomethacin external preparation containing: 0.1 to 3 wt % of indomethacin; 25 to 50 wt % of alcohol; 0.01 to 5 wt % of gelling agent; 5 to 30 wt % of oil component; 20 to 50 wt % of water; and 0.01 to 10 wt % of one or more components selected from the group consisting of glyceryl monostearate, sorbitan monostearate, stearyl alcohol, and polyethylene glycol monostearate.Type: ApplicationFiled: July 22, 2003Publication date: October 27, 2005Inventors: Hiroyuki Shirai, Tatsuya Nakai, Masami Serizawa, Yasuo Shinoda, Toshio Inagi
-
Patent number: 6753330Abstract: The invention provides a solid dispersion composition containing 2-benzyl-5-(4-chlorophenyl)-6-[4-(methylthio)phenyl]-2H-pyridazin-3-one, hydroxypropylmethyl cellulose, and polyoxyethylene polyoxypropylene glycol. The solid dispersion composition of the present invention exhibits the excellent dissolvability of 2-benzyl-5-(4-chlorophenyl)-6-[4-(methylthio)phenyl]-2H-pyridazin-3-one in water, and enables this compound to be constant sequentially and thereby improve absorbability in blood.Type: GrantFiled: April 16, 2003Date of Patent: June 22, 2004Assignee: Kowa Co., Ltd.Inventors: Niichiro Takano, Hiroyuki Kawashima, Yasuo Shinoda, Toshio Inagi
-
Publication number: 20040067909Abstract: An object of present invention is to provide an eye drop which causes no uncomfortable irritation upon instillation and shows favorable long-term storage stability of CPB-I. The eye drop which comprises CPB-I and a polyhydric alcohol, preferably the polyhydric alcohol having a carbonyl value of 5 &mgr;mol/g or lower, can be provided.Type: ApplicationFiled: August 25, 2003Publication date: April 8, 2004Inventors: Haruhiko Naruse, Misato Sano, Yasuo Shinoda, Toshio Inagi
-
Publication number: 20040018235Abstract: The present invention is drawn to a pharmaceutical composition characterized by containing a composition (A) which contains pitavastatin, a salt thereof, or an ester thereof and which initiates release thereof at least in the stomach, and an enteric composition (B) which contains pitavastatin, a salt thereof, or an ester thereof. By use of the controlled release pharmaceutical composition of the present invention, the blood level of pitavastatin can be maintained at an appropriate level immediately after administration over a long period of time. Thus, highly safety and effective treatment of hypercholesterolemia can be performed.Type: ApplicationFiled: June 16, 2003Publication date: January 29, 2004Applicants: KOWA CO., LTD, Nissan Chemical Industries LimitedInventors: Yoshio Tanizawa, Tatsuharu Shimokawa, Hirotada Ogawa, Mayumi Watanabe, Chihiro Ohashi, Hiroyuki Kawashima, Yasuo Shinoda, Toshio Inagi